title: Donor-specific antibodies in allograft rejection: clinical and experimental data.
abstract: The ability of donor-specific major histocompatibility complex alloantibodies to destroy a transplanted organ within minutes, the so-called hyperacute rejection phenomenon, has been known for a long time. It is a clear demonstration of the possible cytotoxic effect of antibodies. Apart from this particular situation, the role of antibodies in inducing acute or chronic allograft rejection remains controversial. Many clinical data have shown that transplant recipients capable of developing class I or class II anti-HLA antibodies experienced shorter survival periods than those who were not. This fact, in accordance with experimental data, only demonstrates that high antibody responders reject a transplant more easily than low responders. More interestingly, there is now increasing evidence that posttransplant appearance of donor-specific alloantibodies, and probably of alloreactive-induced autoantibodies, is strongly correlated with reduced graft survival rate, especially from chronic rejection. We demonstrated that donor-specific HLA antibodies can be found in more than 70% of transplanted kidneys with chronic allograft nephropathy, and that the intragraft presence of such antibodies is significantly correlated with high numbers of plasma cells on early biopsies and C4d deposits, a recognized marker of humoral rejection. It is likely that non-HLA antibodies also play a deleterious role in organ transplant outcome, particularly the heterogeneous group of anti-endothelial cells antibodies, anti-MIC antibodies, autoantibodies and some others with no recognized target. Convincing experimental data, especially using B cell and T cell deficient mice, strongly suggest that B cells and donor-specific antibodies are required for fully developed chronic allograft rejection. The role of antibodies in inducing the cascade of cytokines and growth factors leading to tissue lesions is of increasing interest since it is now possible to control B cell proliferation and antibody production.
authors.affiliation: UPRES EA563, Faculty of Medicine, Dijon, France. gerard.rifle@chu-dijon.fr
authors.forename: Gérard
authors.initials: G
authors.lastname: Rifle
authors.forename: Christiane
authors.initials: C
authors.lastname: Mousson
authors.forename: Laurent
authors.initials: L
authors.lastname: Martin
authors.forename: Fredy
authors.initials: F
authors.lastname: Guignier
authors.forename: Kais
authors.initials: K
authors.lastname: Hajji
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D015415:Biomarkers; D003165:Complement System Proteins / Q000032:analysis; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D008285:Major Histocompatibility Complex; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D015415:Biomarkers; D007518:Isoantibodies; D003165:Complement System Proteins